Seattle-based M3 Biotechnology just closed out an oversubscribed $10 million Series A for its regenerative medicine company that has broad claims: It purports its small molecule drugs “can regrow brain cells” – reversing diseases like Alzheimer’s and Parkinson’s.
Funding will move the company towards clinical trials for its lead compound, MM-201 – an oral drug that works as a growth factor to spur an increase in neuronal connections.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Investors include WRF Capital, the W-Fund and prolific drug developers – and brothers – Bruce and Michael Montgomery.
Photo: Flickr user Liz Henry